TABLE 3.

Compound IDs from their respective studies for those reported in Figures 2–5.

Review ID	Reference ID	IC50 (µM)	Primary assay	References	Review ID	Reference ID	IC50 (µM)	Primary assay	References
1	Snyder_495 (2)	5.1	LKGG-(CV-2)	Osipiuk et al. (2021)	20	XR8-89 (94)	0.11	Z-RLRGG-AMC	Shen et al. (2021)
2	Snyder_530 (3)	6.4			21	XR8-69 (89)	0.37
3 a	Snyder_496	—			22	XR8-23 (72)	0.39
4 a	Snyder_494	—			23	XR8-32-1 (75)	0.97
5	5	17			24	XR8-30 (74)	0.75
6	6	7			25	DY-3-63 (18)	>100
7	7	13			26	ZN-2-193 (21)	>10
8	ZN-2-184 (5)	1.01	Z-RLRGG-AMC	Shen et al. (2021)	27	ZN-2-192 (20)	4.8
9	ZN-2-186 (7)	1.2			28	Jun9-13-7	7.3	(Dabcyl)-FTLRGGAPTKV-(Edans)	Ma et al. (2021)
10	DY2-144 (14)	1.3			29	Jun9-13-9	6.7
11	ZN-2-188–2 (11)	4.3			30	Jun9-53-2	0.89
12	ZN-3-56 (13)	3.9			31	Jun9-72-2	0.67
13	ZN-3-80 (65)	0.59			32	Jun9-87-3	0.80
14	XR8-8 (66)	1.3			33	Jun9-87-2	0.90
15	ZN-3-79 (59)	1.9			34	Jun9-87-1	0.87
16	DY-2-153 (60)	1.8			35	Jun9-75-5	0.56
17	XR8-24 (73)	0.56			36	Jun9-84-3	0.67
18	XR8-65 (86)	0.33			37	Jun9-75-4	0.62
19	XR8-83 (92)	0.21			38	Jun9-85-1	0.66

^a 3 and 4 structures were published in the PDB, prior to publication of (Osipiuk et al., 2021), but excluded from the final publication. The two compounds were presented in this Review to illustrate their structural features.